title: Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
abstract: OBJECTIVE
  To assess components of the fibrinolytic system in the vitreous humour and serum of patients with vitreoretinal disorders.
  
  
  METHODS
  Forty-three samples of vitreous humour and plasma of 43 patients undergoing pars plana vitrectomy for macular hole, macular pucker, retinal detachment or proliferative vitreoretinopathy were evaluated for their content of plasminogen, a2-antiplasmin, plasminogen-activatorinhibitor 1, plasmin-a2-antiplasmin-complex, tissue plasminogen activator, total protein, albumin, d-dimer. Patient groups were compared with each other using the U-test (Mann and Whitney) for non-parametric testing of two independent samples.
  
  
  RESULTS
  The groups of retinal detachment and proliferative vitreoretinopathy had elevated vitreal levels of plasminogenactivator-inhibitor 1 (352.5 and 370.7 ng/mL vs. 1.86 and 56.6 ng/mL, P = non-significant), plasmin-a2-antiplasmincomplex (2416.5 and 1836.2 microg/L vs. 124.2 and 133.4 microg/L, P < 0.001), albumin (0.08 and 0.15 g/dL vs. 0.03 and 0.07 g/dL, P < 0.05) and d-dimer (4.76 and 1.64 microg/mL vs. 0.40 and 0.48 microg/mL, P = non-significant) when compared with patients with macular hole and macular pucker.
  
  
  CONCLUSIONS
  There are significant differences in the vitreal concentration of components of the fibrinolytic system in patients with vitreoretinal disorders. Breakdown of the blood-retinal barrier and complex disease-specific mechanisms are thought to be responsible for an increase of components of the fibrinolytic system in the vitreous.
authors.affiliation: Department of Ophthalmology, Geisinger Medical Center, Danville, Pennsylvania 17822, USA. jnulrich@geisinger.edu
authors.forename: Jan Niklas
authors.initials: JN
authors.lastname: Ulrich
authors.forename: Michael
authors.initials: M
authors.lastname: Spannagl
authors.forename: Anselm
authors.initials: A
authors.lastname: Kampik
authors.forename: Arnd
authors.initials: A
authors.lastname: Gandorfer
mesh_terms: D000368:Aged; D000418:Albumins / Q000032:analysis; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000097:blood; D012163:Retinal Detachment / Q000503:physiopathology; D012164:Retinal Diseases / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*; D012167:Retinal Perforations / Q000503:physiopathology; D012709:Serum Albumin / Q000032:analysis; D018630:Vitreoretinopathy, Proliferative / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*; D014822:Vitreous Body / Q000737:chemistry / Q000503:physiopathology*; D000979:alpha-2-Antiplasmin / Q000032:analysis
chemical_list: D000418:Albumins; D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; D012709:Serum Albumin; D000979:alpha-2-Antiplasmin; C036309:fibrin fragment D; C037742:plasmin-plasmin inhibitor complex; D005341:Fibrinolysin